Cilansetron

Kevin W. Olden, Michael D. Crowell

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Irritable bowel syndrome is an extremely common disorder affecting approximately 10-20% of the population of North America and Europe. This disorder is characterized by abdominal pain and altered bowel habit. The altered bowel habit can take a number of forms. These include a predominant diarrhea form, a form with constipation and one in which patients alternate between diarrhea and constipated forms of the disorder. Irritable bowel syndrome to date has not been associated with any excess mortality. However, the morbidity associated with irritable bowel syndrome is quite high. This mainly takes on the form of impairment in health-related quality of life, interference with activities of daily living and a considerable degree of human suffering. Likewise, the economic impact of irritable bowel syndrome is not trivial and has been estimated to be between US$20 to 30 billion in the United States alone. In an effort to address this common disabling disorder, a number of new drugs have been developed. One of the latest is cilansetron, which is a competitive type 3 serotonin (5-HT3) receptor antagonist. In phase III trials, cilansetron has been shown to be efficacious for the relief of a wide spectrum of symptoms related to irritable bowel syndrome with diarrhea both in male and female patients. By and large, cilansetron is extremely well tolerated and highly efficacious. The most common side effect of cilansetron is constipation, which is seen in 3-12% of subjects at 6 months. Ischemic colitis, a side effect associated with previous drugs of this class, has been seen in eight subjects (six women and two men) to date. All of these ischemic colitis events have been self-limited and did not require surgery. Because of its high degree of efficacy, the fact that it is well tolerated by the overwhelming majority of patients and that it shows efficacy in both genders, cilansetron represents a major advance in the treatment of irritable bowel syndrome with diarrhea predominance.

Original languageEnglish (US)
Pages (from-to)661-666
Number of pages6
JournalDrugs of Today
Volume41
Issue number10
DOIs
StatePublished - Oct 2005

Fingerprint

Irritable Bowel Syndrome
Diarrhea
Ischemic Colitis
Constipation
Habits
Serotonin 5-HT3 Receptor Antagonists
Activities of Daily Living
North America
Psychological Stress
Pharmaceutical Preparations
Abdominal Pain
cilansetron
Economics
Quality of Life
Morbidity
Mortality
Population

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Olden, K. W., & Crowell, M. D. (2005). Cilansetron. Drugs of Today, 41(10), 661-666. https://doi.org/10.1358/dot.2005.41.10.920427

Cilansetron. / Olden, Kevin W.; Crowell, Michael D.

In: Drugs of Today, Vol. 41, No. 10, 10.2005, p. 661-666.

Research output: Contribution to journalArticle

Olden, KW & Crowell, MD 2005, 'Cilansetron', Drugs of Today, vol. 41, no. 10, pp. 661-666. https://doi.org/10.1358/dot.2005.41.10.920427
Olden KW, Crowell MD. Cilansetron. Drugs of Today. 2005 Oct;41(10):661-666. https://doi.org/10.1358/dot.2005.41.10.920427
Olden, Kevin W. ; Crowell, Michael D. / Cilansetron. In: Drugs of Today. 2005 ; Vol. 41, No. 10. pp. 661-666.
@article{4b5a089703ef45e3b89ee64876e2e3c5,
title = "Cilansetron",
abstract = "Irritable bowel syndrome is an extremely common disorder affecting approximately 10-20{\%} of the population of North America and Europe. This disorder is characterized by abdominal pain and altered bowel habit. The altered bowel habit can take a number of forms. These include a predominant diarrhea form, a form with constipation and one in which patients alternate between diarrhea and constipated forms of the disorder. Irritable bowel syndrome to date has not been associated with any excess mortality. However, the morbidity associated with irritable bowel syndrome is quite high. This mainly takes on the form of impairment in health-related quality of life, interference with activities of daily living and a considerable degree of human suffering. Likewise, the economic impact of irritable bowel syndrome is not trivial and has been estimated to be between US$20 to 30 billion in the United States alone. In an effort to address this common disabling disorder, a number of new drugs have been developed. One of the latest is cilansetron, which is a competitive type 3 serotonin (5-HT3) receptor antagonist. In phase III trials, cilansetron has been shown to be efficacious for the relief of a wide spectrum of symptoms related to irritable bowel syndrome with diarrhea both in male and female patients. By and large, cilansetron is extremely well tolerated and highly efficacious. The most common side effect of cilansetron is constipation, which is seen in 3-12{\%} of subjects at 6 months. Ischemic colitis, a side effect associated with previous drugs of this class, has been seen in eight subjects (six women and two men) to date. All of these ischemic colitis events have been self-limited and did not require surgery. Because of its high degree of efficacy, the fact that it is well tolerated by the overwhelming majority of patients and that it shows efficacy in both genders, cilansetron represents a major advance in the treatment of irritable bowel syndrome with diarrhea predominance.",
author = "Olden, {Kevin W.} and Crowell, {Michael D.}",
year = "2005",
month = "10",
doi = "10.1358/dot.2005.41.10.920427",
language = "English (US)",
volume = "41",
pages = "661--666",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - Cilansetron

AU - Olden, Kevin W.

AU - Crowell, Michael D.

PY - 2005/10

Y1 - 2005/10

N2 - Irritable bowel syndrome is an extremely common disorder affecting approximately 10-20% of the population of North America and Europe. This disorder is characterized by abdominal pain and altered bowel habit. The altered bowel habit can take a number of forms. These include a predominant diarrhea form, a form with constipation and one in which patients alternate between diarrhea and constipated forms of the disorder. Irritable bowel syndrome to date has not been associated with any excess mortality. However, the morbidity associated with irritable bowel syndrome is quite high. This mainly takes on the form of impairment in health-related quality of life, interference with activities of daily living and a considerable degree of human suffering. Likewise, the economic impact of irritable bowel syndrome is not trivial and has been estimated to be between US$20 to 30 billion in the United States alone. In an effort to address this common disabling disorder, a number of new drugs have been developed. One of the latest is cilansetron, which is a competitive type 3 serotonin (5-HT3) receptor antagonist. In phase III trials, cilansetron has been shown to be efficacious for the relief of a wide spectrum of symptoms related to irritable bowel syndrome with diarrhea both in male and female patients. By and large, cilansetron is extremely well tolerated and highly efficacious. The most common side effect of cilansetron is constipation, which is seen in 3-12% of subjects at 6 months. Ischemic colitis, a side effect associated with previous drugs of this class, has been seen in eight subjects (six women and two men) to date. All of these ischemic colitis events have been self-limited and did not require surgery. Because of its high degree of efficacy, the fact that it is well tolerated by the overwhelming majority of patients and that it shows efficacy in both genders, cilansetron represents a major advance in the treatment of irritable bowel syndrome with diarrhea predominance.

AB - Irritable bowel syndrome is an extremely common disorder affecting approximately 10-20% of the population of North America and Europe. This disorder is characterized by abdominal pain and altered bowel habit. The altered bowel habit can take a number of forms. These include a predominant diarrhea form, a form with constipation and one in which patients alternate between diarrhea and constipated forms of the disorder. Irritable bowel syndrome to date has not been associated with any excess mortality. However, the morbidity associated with irritable bowel syndrome is quite high. This mainly takes on the form of impairment in health-related quality of life, interference with activities of daily living and a considerable degree of human suffering. Likewise, the economic impact of irritable bowel syndrome is not trivial and has been estimated to be between US$20 to 30 billion in the United States alone. In an effort to address this common disabling disorder, a number of new drugs have been developed. One of the latest is cilansetron, which is a competitive type 3 serotonin (5-HT3) receptor antagonist. In phase III trials, cilansetron has been shown to be efficacious for the relief of a wide spectrum of symptoms related to irritable bowel syndrome with diarrhea both in male and female patients. By and large, cilansetron is extremely well tolerated and highly efficacious. The most common side effect of cilansetron is constipation, which is seen in 3-12% of subjects at 6 months. Ischemic colitis, a side effect associated with previous drugs of this class, has been seen in eight subjects (six women and two men) to date. All of these ischemic colitis events have been self-limited and did not require surgery. Because of its high degree of efficacy, the fact that it is well tolerated by the overwhelming majority of patients and that it shows efficacy in both genders, cilansetron represents a major advance in the treatment of irritable bowel syndrome with diarrhea predominance.

UR - http://www.scopus.com/inward/record.url?scp=30444453269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30444453269&partnerID=8YFLogxK

U2 - 10.1358/dot.2005.41.10.920427

DO - 10.1358/dot.2005.41.10.920427

M3 - Article

C2 - 16389408

AN - SCOPUS:30444453269

VL - 41

SP - 661

EP - 666

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 10

ER -